News

Precision Radiation Technique for Prostate Cancer May Reduce Short-Term Toxicity

Beyond Brachytherapy: Does Adding EBRT Benefit Those With Intermediate-Risk Prostate Cancer?

Researchers Link Metabolic Biomarkers With Increased Risk of Prostate Cancer in Black Men

Prostate Cancer Prognosis in Asian Versus White Men

Predicting Recurrence of Prostate Cancer With PSMA PET Imaging

ASCOBT 2023: Can Exercise Improve Quality of Life in Patients on Androgen-Deprivation Therapy?

Patient Point of View: The Monetary Impact of Treatment for Metastatic Prostate Cancer

ASCOBT 2023: Radiomic Model May Improve the Ability to Predict Prostate Cancer Recurrence

ASCOBT 2023: Interplay of DNA Damage Response Variants and the Transcriptome in East Asian Patients With Prostate Cancer

ASCOBT 2023: Can Exercise and Psychotherapy Improve Sexual Health in Patients With Prostate Cancer?

FDA Approves Niraparib Combination Therapy for BRCA-Mutated Metastatic Castration-Resistant Prostate Cancer

ASCOBT 2023: Clinical Implications of Dosimetric Feasibility Study of Radiotherapy for Prostate Cancer

Using Artificial Intelligence to Map Cancer in the Prostate

Can a New Target in Prostate Cancer Unlock Better Outcomes Across Cancer Types?

Diagnostic and Treatment Disparities Among Hispanic Men With Metastatic Prostate Cancer

Primary Survival Analysis of ENZAMET: Role of Enzalutamide in Testosterone Suppression in Prostate Cancer

Comparing the Effect of Darolutamide Versus Enzalutamide on Post-Treatment Testosterone Levels

Safety Data From TALAPRO-2 Trial of Talazoparib Plus Enzalutamide in Metastatic Prostate Cancer

Health-Related Quality of Life Data From PROpel on Abiraterone Plus Olaparib in Prostate Cancer

New Angles Explored for Treating High-Volume Metastatic Castration-Sensitive Prostate Cancer

Using Genetically Adjusted PSA Levels to Improve Prostate Cancer Screening

Should Enzalutamide and Abiraterone Be Combined in Conjunction With Long-Term Androgen-Deprivation Therapy?

ASCO 2023: Real-World Comparison of Darolutamide, Enzalutamide, and Apalutamide in Nonmetastatic Prostate Cancer

ASCO 2023: Can Nutritional Programs Mitigate Nutritional Risks of Androgen-Deprivation Therapy for Prostate Cancer?

ASCO 2023: Traditional Genetic Counseling Versus Patient-Driven Web Tools for Prostate Cancer Germline Testing

ASCO 2023: Does PSA Nadir After Radiotherapy Impact Outcomes in Localized Prostate Cancer?

FDA Approves Talazoparib With Enzalutamide for HRR-Mutated Metastatic Prostate Cancer

ASCO 2023: Impact of Irradiation in Low-Volume Metastatic Prostate Cancer

ASCO 2023: Black and White Patients Fared Differently When Treated With Combination Therapy for Prostate Cancer

ASCO 2023: Can HRR Gene Alterations Predict Prognosis in Metastatic Castration-Resistant Prostate Cancer?

ASCO 2023: AI-Based Biomarker and Response to Long-Term Androgen-Deprivation Therapy

ASCO 2023: TALAPRO-2 Update of Talazoparib Plus Enzalutamide in Metastatic Prostate Cancer With HRR Gene Alterations

ASCO 2023: Early-Phase Trial of Radionuclide Therapy Plus Olaparib in Metastatic Prostate Cancer

FDA Approves Olaparib-Based Combination for BRCA-Mutated Metastatic Prostate Cancer

FDA Approves First Radiohybrid PSMA-Targeted PET Imaging Agent for Prostate Cancer

Are Older Men Being Overscreened for Prostate Cancer? California Survey Results Suggest Yes

AUA 2023: Update on Novel Radioligand Therapy for Castration-Resistant Prostate Cancer

AUA 2023: Patients’ Preferences Take Center Stage in Study of Androgen-Deprivation Therapy

AUA 2023: ARAMIS Trial Update on Darolutamide in Nonmetastatic Castration-Resistant Prostate Cancer

Transgender Women May Be at Risk for Prostate Cancer, Study Reveals

AUA 2023: Disparities Among Survivorship Programs for Genitourinary Cancer

$1.7M Grant for Novel Prostate Cancer Treatment Awarded to Sanford-Burnham Researcher

AUA 2023: Risk of Cardiovascular Events After Androgen-Deprivation Therapy for Prostate Cancer

AUA 2023: How Does AI Model Compare With Radiologists in Detecting Prostate Cancer on MRI?

AACR 2023: Darolutamide-Based Combination Therapy for Metastatic Castration-Resistant Prostate Cancer

AACR 2023: Does Inflammation Tie Together Prostate Cancer, Colorectal Cancer, and Ulcerative Colitis?

AACR 2023: Researchers Focus on Solving the Enzalutamide Efficacy Puzzle in Prostate Cancer

Phase II EXTEND Trial: Metastasis-Directed Therapy for Advanced Prostate Cancer

Novel Monoclonal Antibody Shows Activity in High-Risk Prostate Cancers

AACR 2023: Novel Targeted Combination Therapy for Metastatic Castration-Resistant Prostate Cancer

NCCN 2023: Case-Based Presentation Features Updates on Managing Metastatic Prostate Cancer

AACR 2023: Prostate Cancer Mortality Disparities in Men of African Ancestry Living in Florida

AACR 2023: Racial Disparity in Outcomes After Prostatectomy

Is Nadir PSA Value an Independent Predictor of Survival in Prostate Cancer?

Screening for Colorectal Cancer Among Prostate Cancer Survivors: Focus on Physical and Mental Health

Can Darolutamide Improve Outcomes in High-Risk Prostate Cancer? Researchers Intend to Find Out

Darolutamide Plus Testosterone Cypionate in 'Extreme Bipolar Androgen Therapy' for Prostate Cancer